CSRxP Launches TV & Digital Ad Campaign Urging Congress to Pass the CREATES Act


March 8, 2018
Contact: Will@csrxp.org
( 202) 286-4682

The Campaign for Sustainable Rx Pricing (CSRxP) launched an advertising campaign today calling on Congress to pass the CREATES Act as part of the omnibus spending package this month.

The bill, which the CBO projects would save taxpayers $3.8 billion, targets Big Pharma’s abuse of Risk Evaluation and Mitigation Strategies (REMS) as a pretext for thwarting generic competition and maintaining monopoly pricing power.

The ad, which will air on television and digitally in the Washington, DC market, and is backed up by a six figure investment, highlights the broad, bipartisan support for CREATES on both sides of the aisle and across a wide array of organizations representing consumers, doctors, nurses, hospitals, payers, and patients. 44 of these groups recently sent a letter to congressional leadership in support of the bill.

In just the last month, momentum to pass this legislation has grown, with Representatives Mark Meadows, Peter Welch, Todd Rokita, Marcy Kaptur, Francis Rooney, Mike Gallagher, Carol Shea-Porter, as well as Senators John Kennedy and Tina Smith adding their names to the list of co-sponsors. As the lead sponsor of the bill in the House, Rep. Tom Marino, said this week, “it’s going to be done and it’s going to be done this year.”

“This is a golden opportunity for Congress to fulfill a key campaign promise and make a tangible impact on out-of-control prescription drug prices,” said CSRxP spokesman Will Holley. “This market-based reform would put an end to some of Big Pharma’s most egregious abuses and save billions of dollars for taxpayers, job creators, and, most importantly, the patients who depend on these drugs to stay alive.”

Click here to view the spot.

About the Campaign for Sustainable Rx Pricing
The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses – promoting bipartisan, market-based solutions to lower drug prices in America.